186P Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy

P.A Fasching,W Xue,M Huang,Y Xin,W Pan,J Truscott,J O'Shaughnessy,V Karantza,A Haiderali,F Yang

doi:10.1016/j.annonc.2022.07.221

186P Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy

P.A Fasching, W Xue + Show 8 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.221

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
Citations: 1	License type: publisher-specific-oa

Affiliation: Institute of Group Analysis, MSD (United States), Texas Oncology

#Early-stage Triple-negative Breast Cancer Patients #Early-stage Triple-negative Breast Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Event-free survival (EFS) is a commonly used primary endpoint in neoadjuvant studies for triple-negative breast cancer (TNBC) as overall survival (OS) requires extended follow-up and significant patient resources. However, the surrogacy of EFS for OS has yet to be established. This study evaluated the association between EFS and OS among early-stage TNBC patients who received neoadjuvant therapy.

Full Text